Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: The aromatic group is essential for the activity

Bioorganic and Medicinal Chemistry

Volumn 10, Issue 12, 2002, Pages 3829-3848

  Kazuta, Yuji ^a   Tsujita, Ryuichi ^b   Yamashita, Kanako ^b   Uchino, Shigeo ^c   Kohsaka, Shinichi ^c   Matsuda, Akira ^a   Shuto, Satoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ASAHI CHEMICAL INDUSTRY CO   (Japan)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 NAPHTHYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (2 FLUOROPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (2 METHYLPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (2 NAPHTHYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (3 FLUOROPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (3 METHYLPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (4 FLUOROPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 (4 METHYLPHENYL) 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 1 PHENYL 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 2 (1 AMINOPROPYL) N,N DIETHYLCYCLOPROPANECARBOXAMIDE; AMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; CYCLOPROPANES; HYDROCARBONS, AROMATIC; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036976386     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00346-2     Document Type: Article

References (50)

1. Dingledine R., Borges K., Bowie D., Traynelis S. Pharmacol. Rev. 51:1999;7.
2. Bräuner-Osbornel H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaad-Larsen P. J. Med. Chem. 43:2000;2609.
3. Collingridge G.L., Watkins J.C. The NMDA Receptor. 1994;IRL Press at Oxford Univ. Press, Oxford, UK.
4. (a) Willetts J., Balster R.L., Leander J.D. Trends Pharmacol. Sci. 11:1990;423
5. (b) Tricklebank M.D., Singh L., Oles R.J., Preston C., Iversoen S.D. Eur. J. Pharmacol. 167:1989;127
6. (c) Rogawski M.A. Trends Pharmacol. Sci. 14:1993;325.
7. Olney J.W., Labruyere J., Price M.T. Science. 244:1989;1360.
8. (a) Meldrum B.S., Croucher M.J., Czuczwar S.J., Collins J.F., Curry K., Joseph M., Stone T.W. Neuroscience. 9:1983;925
9. (b) Hogan M.J., Gjedde A., Hakem A.M. J. Neurochem. 58:1992;186.
10. Compound (±)-1 had previously been called 'midalcipran'. However, since the clinical studies began, the name 'milnacipran' has generally been used for (±)-1.
11. (a) Briley M. Drugs Future. 11:1986;21
12. (b) Moret C., Charveron M., Finberg J.P.M., Cozinier J.M., Briley M. Neuropharmacology. 24:1985;1211
13. (c) Bonnaud B., Cousse H., Mouzin G., Briley M., Stenger A., Fauran F., Couzinier J.-P. J. Med. Chem. 30:1987;318
14. (d) Ansseau M., Papart P., Troisfontaines B., Bartholome F., Bataille M., Charles G., Schittecatte M., Darimont P., Devoitille J.M. Psychopharmacology. 114:1994;131
15. (e) Artigas F. CNS Drugs. 4:1995;79.
16. Shuto S., Takada H., Mochizuki D., Tsujita R., Hase Y., Ono S., Shibuya N., Matsuda A. J. Med. Chem. 38:1995;2964.
17. (a) Shuto S., Ono S., Hase Y., Kamiyama N., Takada H., Yamashita K., Matsuda A. J. Org. Chem. 61:1996;915
18. (b) Ono S., Shuto S., Matsuda A. Tetrahedron Lett. 37:1996;221
19. (c) Shuto S., Ono S., Hase Y., Kamiyama N., Matsuda A. Tetrahedron Lett. 37:1996;641
20. (d) Shuto S., Ono S., Hase Y., Ueno Y., Noguchi T., Yoshii K., Matsuda A. J. Med. Chem. 39:1996;4844
21. (e) Shuto S., Ono S., Imoto H., Yoshii K., Matsuda A. J. Med. Chem. 41:1998;3507
22. (f) Noguchi T., Ishii K., Imoto H., Otubo Y., Shuto S., Ono S., Matsuda A., Yoshii K. Synapse. 31:1999;87
23. (g) Kazuta Y., Shuto S., Matsuda A. Tetrahedron Lett. 41:2000;5373
24. (h) Shuto S., Yoshii K., Matsuda A. Jpn. J. Pharmacol. 85:2001;207
25. (i) Kazuta Y., Shuto S., Abe H., Matsuda A. J. Chem. Soc., Perkin Trans. 1. 2001;599
26. (j) Uchino S., Watanabe W., Nakamura T., Shuto S., Kazuta Y., Matsuda A., Nakazima-Iijima S., Kohsaka S., Kudo Y., Mishina M. FEBS Lett. 69:2001;2007
27. (k) Kazuta Y., Tsujita R., Ogawa K., Hokonohara T., Yamashita K., Morino K., Matsuda A., Shuto S. Bioorg. Med. Chem. 10:2002;1777
28. (l) Kazuta Y., Tsujita R., Uchino S., Kamiyama N., Mochizuki D., Yamashita K., Ohmori Y., Yamashita A., Yamamoto T., Kohsaka S., Matsuda A., Shuto S. J. Chem. Soc., Perkin Trans. 1. 2002;1199
29. (m) Ono S., Ogawa K., Yamashita K., Yamamoto T., Kazuta Y., Matsuda A., Shuto S. Chem. Pharm. Bull. 50:2002;966.
30. Wong H.N.C., Hon M.-Y., Tse C.-Y., Yip Y.-C. Chem. Rev. 89:1989;165.
31. (a) Reviews on asymmetric cyclopropanations: Singh V.K., DattaGupta A., Sekar G. Synthesis. 1997, 137.
32. (b) Doyle M.P., Protopopova M.N. Tetrahedron. 54:1998;7919.
33. (a) Examples of synthesis of 1,2-disubstituted chiral cyclopropanes via chemical or enzymatic optical resolutions: Laumen K., Schneider M. Tetrahedron Lett. 26:1985;2073
34. (b) Ader U., Breitgoff D., Klein P., Laumen K.E. J. Org. Chem. 30:1989;1793
35. (c) Grandjean D., Chuche P.P.J. Tetrahedron. 47:1991;1215
36. (d) Silva C.B.-D., Benkouider A., Pale P. Tetrahedron Lett. 41:2000;3077
37. (e) Zhang X., Hodgetts K., Rachwal S., Zhao H., Wasley J.W.F., Craven K., Brodbeck R., Kieltyka A., Hoffman D., Bacolod M.D., Girard B., Tran J., Thurkauf A. J. Med. Chem. 43:2000;3923.
38. (a) Examples of synthesis of 1,2-disubstituted chiral cyclopropanes from chiral synthons: Yamanoi K., Ohfune Y. Tetrahedron Lett. 29:1988;1181
39. (b) Shimamoto K., Ohfune Y. Tetrahedron Lett. 30:1989;3803
40. (c) Pirrung M.C., Dunlap S.E., Trinks V.P. Helv. Chim. Acta. 72:1989;1301
41. (d) Morikawa T., Sasaki H., Hanai R., Shibuya A., Taguchi T. J. Org. Chem. 59:1994;97
42. (e) Critcher D.J., Connolly S., Wills M. J. Org. Chem. 62:1997;6638
43. (f) Takemoto Y., Baba Y., Saha G., Nakao S., Iwata C., Tanaka T., Ibuka T. Tetrahedron Lett. 41:2000;3653.
44. Kazuta Y., Matsuda A., Shuto S. J. Org. Chem. 67:2002;1669.
45. N2 reaction pathway: Yamamoto I., Sekine M., Hata T. J. Chem. Soc., Perkin Trans. 1. 1980;306.
46. (a) Benedetti F., Berti F., Risaliti A. Tetrahedron Lett. 34:1993;6443
47. (b) Brown A.C., Carpino L.A. J. Org. Chem. 50:1985;1749.
48. The optical purity was determined by chiral HPLC.
49. Asano T., Ikegaki I., Satoh S., Mochizuki D., Hidaka H., Suzuki Y., Shibuya M., Sugita K. Br. J. Pharmacol. 103:1991;1935.
50. 50=8.7±0.5 μM (4b), 7.8±0.7 μM (4c).